newsare.net
AstraZeneca's new $2 billion facility in Tuas, when completed in 2029, will be the company's first end-to-end antibody drug conjugates (ADCs) production site globally. Unlike conventional chemotherapy drugs which are unable to distinguish between healthyAstraZeneca to open new $2b facility in Tuas by 2029, promises 800 jobs
AstraZeneca's new $2 billion facility in Tuas, when completed in 2029, will be the company's first end-to-end antibody drug conjugates (ADCs) production site globally. Unlike conventional chemotherapy drugs which are unable to distinguish between healthy and cancerous cells, ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. Speaking at the ground-breaking ceremony on Thursday (Nov 7), Deputy Prime Minister and Minister for Trade and Industry Gan Kim Yong said that the new facility will «be a significant boost to Singapore's biopharmaceutical industry» and will help build up Singapore’s competitive advantage in ADC manufacturing . He added that “this facility will provide a shot in the arm for Singapore’s biopharmaceutical industry with world-leading ADC technological capabilities”. AstraZeneca’s 58-acre (about the size of 31 football fields) greenfield facility in Tuas South will incorporate all four steps of the manufacturing process in one site, and it will also utilise artificial intelligence and digital platforms. Read more